Industry Updates
This broad category includes articles concerning health insurance costs, carrier and health plan news, changing benefits technology, and surveys by the Kaiser Family Foundation and others on employee benefits.
Controversial California legislation requiring drug companies to justify treatment costs and price hikes jumped one more hurdle Thursday, just a few weeks before the end of the legislative session.
Nearly half of California hospitals received a grade of C or lower for patient safety on a national report card aimed at prodding medical centers to do more to prevent injuries and deaths.
More than two dozen doctors, pharmacists and business owners were charged Thursday in an alleged $40 million medical-insurance scam in Orange County and elsewhere that officials said “played with patients’ lives.”
With deadlines looming to file plans for next year’s Affordable Care Act marketplaces, health insurers are struggling to respond to mixed signals from the Trump administration, delaying key business decisions and scouring Twitter for hints from Washington about the law’s future.
The pharmaceutical industry for years has fended off calls for government to controls prices despite the growing uproar over soaring prescription drug costs.,
The House on Wednesday passed a bill that could protect and keep costs down for small and mid-sized self-insured employers.
HHS and Congress will continue to align their efforts to replace fee-for-service payments with value based alternatives.
A proposal in California for a single-payer healthcare system would dramatically expand the state government's presence in medical care and slash the role of insurance companies.
White House officials made a new offer to conservative House Republicans late Monday on the GOP's failed health care bill, hoping to resuscitate a measure that crashed spectacularly less than two weeks ago.
Anthem, a major health insurer, is “leaning toward exiting” many of the areas in which it sells insurance on the Affordable Care Act exchanges, according to Wall Street analysts who met with the company.